The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Phase II Study of the Anti–Insulin-Like Growth Factor Type 1 Receptor Antibody CP-751,871 in Combination With Paclitaxel and Carboplatin in Previously Untreated, Locally Advanced, or Metastatic Non–Small-Cell Lung Cancer
Open accessAbstract
Purpose: We conducted a phase II study of combination of the anti–insulin-like growth factor 1 receptor antibody CP-751,871 with paclitaxel and carboplatin (PCI) in advanced treatment-naïve non–small-cell lung cancer (NSCLC). Patients and Methods: Patients were randomly assigned (2:1) to paclitaxel 200 mg/m 2 , carboplatin (area under the plasma concentration-time curve of 6), and CP-751,871 10 to 20 mg/kg (PCI 10 , PCI 20 ) or paclitaxel and carboplatin alone (PC) every 3 weeks for up to six cycles. PCI 10-20 patients could continue CP-751,871 (figitumumab) treatment after chemotherapy discontinuation. Patients treated with PC experiencing disease progression were eligible to receive CP-751,871 at investigator's discretion. An additional nonrandomized single-arm cohort of 30 patients with nonadenocarcinoma tumor histology receiving PCI 20 was enrolled on completion of the randomized study. Results: A total of 156 patients were enrolled onto the randomized portion of the study. Safety and efficacy information are available for 151 patients (98 patients treated with PCI and 53 patients treated with PC). Forty-eight patients treated with PCI received PCI 10 and 50 patients received PCI 20 in two sequential stages. Twenty of 53 patients treated with PC received CP-751,871 after disease progression. PCI was well tolerated. Fifty-four percent of patients treated with PCI and 42% of patients treated with PC had objective responses. Sixteen of 23 patients assessable for efficacy in the nonrandomized single-arm extension cohort also responded to treatment. Of note, 14 of 18 randomly assigned and 11 of 14 nonrandomly assigned patients treated with PCI with squamous cell carcinoma histology had response to treatment, including nine objective responses in bulky disease. Responses were also observed in two patients with squamous histology receiving CP-751,871 on PC discontinuation. PCI 20 /PC hazard ratio for progression-free survival was 0.8 to 0.56, according to censorship. Conclusion: These data suggest that PCI 20 is safe and effective in patients with NSCLC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Paclitaxel–Carboplatin Alone or with Bevacizumab for Non–Small-Cell Lung Cancer
Sandler, A., Gray, R., Perry, M. C., Brahmer, J., Schiller, J. H., Dowlati, A., Lilenbaum, R., & Johnson, D. H. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa061884 · Cited by 5,761
Optimal two-stage designs for phase II clinical trials.
Simon, R. (1989) · Controlled Clinical Trials · doi:10.1016/0197-2456(89)90015-9 · Cited by 3,636
Scagliotti, G. V., Parikh, P., von Pawel, J., Biesma, B., Vansteenkiste, J., Manegold, C., Serwatowski, P., Gatzemeier, U., Digumarti, R., Zukin, M., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.0375 · Cited by 3,203
Johnson, D. H., Fehrenbacher, L., Novotny, W. F., Herbst, R. S., Nemunaitis, J. J., Jablons, D. M., Langer, C. J., DeVore, R. F., Gaudreault, J., Damico, L. A., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.11.022 · Cited by 1,937
Self-citationThe new World Health Organization classification of lung tumours
Brambilla, E., Travis, W. D., Colby, T. V., Corrin, B., & Shimosato, Y. (2001) · European Respiratory Journal · doi:10.1183/09031936.01.00275301 · Cited by 1,131
Functionally significant insulin-like growth factor I receptor mutations in centenarians
Suh, Y., Atzmon, G., Cho, M.-O., Hwang, D., Liu, B., Leahy, D. J., Barzilai, N., & Cohen, P. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0705467105 · Cited by 703
The 2004 World Health Organization classification of lung tumors
Beasley, M. B., Brambilla, E., & Travis, W. D. (2005) · Seminars in Roentgenology · doi:10.1053/j.ro.2005.01.001 · Cited by 564
Plasma Levels of Insulin-Like Growth Factor-I and Lung Cancer Risk: a Case-Control Analysis
Yu, H., Spitz, M. R., Mistry, J., Gu, J., Hong, W. K., & Wu, X. (1999) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/91.2.151 · Cited by 554
Cohen, B. D., Baker, D. A., Soderstrom, C., Tkalcevic, G., Rossi, A. M., Miller, P. E., Tengowski, M. W., Wang, F., Gualberto, A., Beebe, J. S., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-1070 · Cited by 365
Self-citationIGF1R signalling and its inhibition
Riedemann, J., & Macaulay, V. M. (2006) · Endocrine-Related Cancer · doi:10.1677/erc.1.01280 · Cited by 301
Haluska, P., Shaw, H. M., Batzel, G. N., Yin, D., Molina, J. R., Molife, L. R., Yap, T. A., Roberts, M. L., Sharma, A., Gualberto, A., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1118 · Cited by 270
Self-citationMorgillo, F., Kim, W.-Y., Kim, E. S., Ciardiello, F., Hong, W. K., & Lee, H.-Y. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2077 · Cited by 251
Shevah, O., & Laron, Z. (2007) · Growth Hormone & IGF Research · doi:10.1016/j.ghir.2006.10.007 · Cited by 190
Pirker, R., Szczesna, A., von Pawel, J., Krzakowski, M., Ramlau, R., Park, K., Gatzemeier, U., Bajeta, E., Emig, M., & Pereira, J. R. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.26.15_suppl.3 · Cited by 172
Manegold, C., von Pawel, J., Zatloukal, P., Ramlau, R., Gorbounova, V., Hirsch, V., Leighl, N., Mezger, J., Archer, V., & Reck, M. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.25.18_suppl.lba7514 · Cited by 168
Lacy, M. Q., Alsina, M., Fonseca, R., Paccagnella, M. L., Melvin, C. L., Yin, D., Sharma, A., Enriquez Sarano, M., Pollak, M., Jagannath, S., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.9319 · Cited by 163
Self-citationGrowth factor receptor interplay and resistance in cancer
Jones, H. E., Gee, J. M. W., Hutcheson, I. R., Knowlden, J. M., Barrow, D., & Nicholson, R. I. (2006) · Endocrine Related Cancer · doi:10.1677/erc.1.01275 · Cited by 139
Chang, Y. S., Wang, L., Liu, D., Mao, L., Hong, W. K., Khuri, F. R., & Lee, H. (2002) · PubMed · Cited by 136
Kato, T., Hayama, S., Yamabuki, T., Ishikawa, N., Miyamoto, M., Ito, T., Tsuchiya, E., Kondo, S., Nakamura, Y., & Daigo, Y. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1297 · Cited by 118
Yamazaki, S., Sekine, I., Matsuno, Y., Takei, H., Yamamoto, N., Kunitoh, H., Ohe, Y., Tamura, T., Kodama, T., Asamura, H., et al. (2005) · Lung Cancer · doi:10.1016/j.lungcan.2005.01.008 · Cited by 117
Pirker, R., Ramlau, R., Schuette, W., Zatloukal, P., Ferreira, I., Lillie, T., & Vansteenkiste, J. F. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.0748 · Cited by 114
M6P/IGF2R is mutated in squamous cell carcinoma of the lung
Kong, F., Anscher, M. S., Washington, M. K., Killian, J. K., & Jirtle, R. L. (2000) · Oncogene · doi:10.1038/sj.onc.1203437 · Cited by 108
Spitz, M. R., Barnett, M. J., Goodman, G. E., Thornquist, M. D., Wu, X., & Pollak, M. (2002) · PubMed · Cited by 74
Neuroendocrine differentiation as a prognostic factor in non-small cell lung cancer
Carles, J., Rosell, R., Ariza, A., Pellicer, I., Sanchez, J. J., Fernandez-Vasalo, G., Abad, A., & Barnadas, A. (1993) · Lung Cancer · doi:10.1016/0169-5002(93)90181-v · Cited by 70
Ardizzoni, A., Tiseo, M., Boni, L., Rosell, R., Fossella, F. V., Schiller, J. H., Paesmans, M., Radosavljevic, D. Z., Paccagnella, A., Mazzanti, P., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.24.18_suppl.7011 · Cited by 62
Expression of insulin-like growth factor receptors I and II in normal human lung and in lung cancer
Kaiser, U., Schardt, C., Brandscheidt, D., Wollmer, E., & HAVEMANN, K. (1993) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/bf01215985 · Cited by 60
Treatment of Advanced Non–Small-Cell Lung Cancer With Two-Drug Combinations
Bunn, P. A. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.20.17.3565 · Cited by 57
Chiappori, A., Haura, E. B., Rodriguez, F. A., Boulware, D. C., Kapoor, R., Neuger, A. M., Lush, R. M., Padilla, B., Burton, M. K., Williams, C. C., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1508 · Cited by 44
Clinical significance of insulin receptor substrate-I down-regulation in non-small cell lung cancer
Chang, H., Choi, Y., Moon, J. H., Kim, H. K., Kim, S. H., Shin, D., Chang, J., Ahn, C. W., Kim, S., & Chang, Y. S. (2006) · Oncology Reports · doi:10.3892/or.16.6.1205 · Cited by 38
American Association for Cancer Research Annual Meeting 2018
Martín, Y. D. P. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30329-2 · Cited by 35
The Consequences of Insulin-Like Growth Factors/Receptors Dysfunction in Lung Cancer
Pavelić, J., Križanac, Š., Kapitanović, S., Pavelić, L., Samaržija, M., Pavičić, F., Spaventi, Š., Jakopović, M., Ivanovi-Herceg, Z., & Pavelić, K. (2004) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2004-0232oc · Cited by 20
Cited by
Lung cancer: Biology and treatment options
Lemjabbar-Alaoui, H., Hassan, O. U., Yang, Y.-W., & Buchanan, P. (2015) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2015.08.002 · Cited by 1,014
Lung cancer: New biological insights and recent therapeutic advances
Ramalingam, S. S., Owonikoko, T. K., & Khuri, F. R. (2011) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20102 · Cited by 471
Nguyen, K.-S. H., Kobayashi, S., & Costa, D. B. (2009) · Clinical Lung Cancer · doi:10.3816/clc.2009.n.039 · Cited by 437
The proliferating role of insulin and insulin-like growth factors in cancer
Gallagher, E. J., & LeRoith, D. (2010) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2010.06.007 · Cited by 380
Rajski, M., Zanetti-Dällenbach, R., Vogel, B., Herrmann, R., Rochlitz, C., & Buess, M. (2010) · BMC Medicine · doi:10.1186/1741-7015-8-1 · Cited by 355
Metadata
- Authors
- Karp, D. D., Paz-Ares, L. G., Novello, S., Haluska, P., Garland, L., Cardenal, F., Blakely, L. J., Eisenberg, P. D., Langer, C. J., Blumenschein, G., Johnson, F. M., Green, S., & Gualberto, A.
- Venue
- Journal of Clinical Oncology
- Published
- 2009-05-20
- Volume
- 27
- Issue
- 15
- Pages
- 2516-2522
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2136137911
- Cited by
- 260
- References
- 31
- FWCI
- 38.12
- Type
- journal article
- Language
- en
- Status
- Retracted
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.